Navigation Links
Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th
Date:11/6/2009

AURORA, Ontario, Nov. 6 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: "HBP" / Pink Sheets: HXBPF) today announced that John Docherty, president and chief operating officer, will present at Merriman Curhan Ford's 6th annual Investor Summit on November 10, 2009 at 4:00 PM at the Sofitel Hotel in New York City. Mr. Docherty will provide an overview of the Company's leading product development programs L-DOS47 and Topical Interferon Alpha-2b. The slide show portion of the presentation will be posted on the Company's website, www.helixbiopharma.com, on November 10th, 2009.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is listed on the TSX and FSE under the symbol "HBP" and on the OTCQX International Market under the symbol "HXBPF."

About Merriman Curhan Ford

Merriman Curhan Ford (Nasdaq: MERR) is a financial services firm focused on fast-growing companies and the institutions that invest in them. The company offers high-quality investment banking, equity research, institutional services and corporate & venture services, and specializes in five growth industry sectors: CleanTech, Consumer, Media & Internet, Health Care, Natural Resources and Technology. For more information, please go to www.mcfco.com.

    For further information contact:
    Investor Relations
    Robert Flamm, Ph.D.
    Russo Partners LLC
    Tel: (212) 845-4226
'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AlphaHelix Presents AmpXpress(TM) at the BIOTECHNICA Show
2. Helix BioPharma Closes Private Placement
3. Helix BioPharma Announces $13.5 Million Private Placement
4. Helix Biopharma to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
5. Double Helix Strengthens its Strategic Pricing and Reimbursement Practice with Hire of Caryn Zieses
6. New and Updated Online Tutorials for dbGaP, GAD, and DGV from OpenHelix
7. Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference
8. Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update
9. Helix BioPharma to Present at the BioFinance 2009 Conference
10. Double Helix Appoints Ann Stuchiner Vice President of US Consulting Division
11. Helix BioPharma Announces Q2 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire/ - iCo Therapeutics ... today reported financial results for the six months ... are expressed in Canadian dollars and presented under ... Quarter 2014 Highlights , Announced top-line ... (VA) primary endpoint for subjects enrolled in the ...
(Date:8/29/2014)... San Antonio, TX (PRWEB) August 29, 2014 ... 9001:2008 and ISO 13485:2003 certified, GAMP® 5 compliant ... been awarded an international Phase II clinical trial ... non-Hodgkin’s lymphoma. , Throughout this trial, Intrinsic Imaging ... but not limited to, protocol and charter development, ...
(Date:8/28/2014)... A new research platform uses a laser ... structures undergoing stress and heating, an approach ... for microelectronics and batteries., This new technique, ... how heating and the surface stress of ... have discussed the merits of surface-stress influence ...
(Date:8/28/2014)... ATLANTA , Aug. 28, 2014   SunTrust ... of three industry veterans to its equity research ... "Our ongoing expansion in equity research demonstrates ... with unique insights to enhance their investment decision ... Equities at STRH.  "We continue to make significant ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3
... Mass. (Nov. 23, 2010) Pity the female fruit fly. Being ... less a proposal, you have to act like a girl, even ... your hands. Like most animals, fruit flies must distinguish ... fruit fly suspects he,s encountered a female, he,ll court; when he ...
... Nottingham have made a major breakthrough that could help shape ... that 3-D molecular structures can be built on a surface. ... the development of new nano devices such as cutting-edge optical ... paper published in the prestigious journal Nature Chemistry , ...
... Since graphene was first isolated in 2004 with the ... the material to discover its potential applications. A single ... electronics to biosensors to flexible displays, graphene is strong, ... But what can we do with this new material? ...
Cached Biology Technology:Battle of the sexes, fruit-fly style 2World-first to provide building blocks for new nano devices 2Doctoral candidate publishes on graphene's potential with NSF support 2Doctoral candidate publishes on graphene's potential with NSF support 3Doctoral candidate publishes on graphene's potential with NSF support 4
(Date:8/29/2014)... have made some surprising discoveries about the body,s ... virus (SIV), the team found that specialized cells ... responders to viral invasion and are the source ... interleukin-1 beta (IL-1β). , Though aimed at ... the gut epithelium that provides a barrier to ...
(Date:8/29/2014)... SAN ANTONIO (Aug. 29, 2014) Scientists at the ... the School of Medicine at the UT Health Science ... longevity in the tissues of the longest-lived rodent, the ... factor in the cells of naked mole rats protects ... disposer for damaged and obsolete proteins. , The factor ...
(Date:8/29/2014)... Until recently, little has been known about what genetic ... team of scientists, one of whom is a University ... showing that genes controlling the development of the brain ... domestication., The study was published Aug. 28 in ... It is online at http://www.sciencemag.org/ ., The domestication ...
Breaking Biology News(10 mins):The early cost of HIV 2Factor in naked mole rat's cells enhances protein integrity 2New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3
... 02 April 2011: Thalidomide has shown potential to be used ... to data presented at the International Liver CongressTM 2011.1 ... grossly curative resection surgical removal of the cancerous ... free survival rate (65%) compared to placebo (33%). However, ...
... SPAINIrrigating agricultural crops places huge demands on water ... where agriculture is a major contributor to the ... comes from the agricultural sector. The excessive use ... concerns in Mediterranean countries, where rising demand has ...
... Ore. Engineers at Oregon State University have ... in the production of low-temperature, microchannel heat exchangers ... technology much less expensive for many commercial applications. ... researchers say, in next-generation computers, lasers, consumer electronics, ...
Cached Biology News:Thalidomide shows efficacy as adjuvant therapy for hepatocellular carcinoma patients 2Research on satellite imagery aims to advance sustainable agriculture 2Advance in microchannel manufacturing opens new industry applications 2
AVOID FREEZE/THAW CYCLES. Recognizes the UCP-2 protein....
... The new Vivaspin 2 bridges the gap ... centrifugal concentrators. This device combines the speed ... internal surface and membrane area for superior ... with a choice of PES, Cellulose Triacetate ...
... Recognizes VAMP-2 (Vesicle-Associated Membrane ... epitope does not share homology ... REACTIVITIES: It is expected ... react with human, Macaca multata ...
... Transporter 2 (VMAT2). An antibody made to ... band at ~55 kDa in postnuclear supernatants ... in wild type cells (2). Some additional ... were also detected and remain unaffected by ...
Biology Products: